PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012
- PMID: 25953846
- DOI: 10.1136/bjophthalmol-2015-306733
PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012
Abstract
Background/aims: The epidemiology of Graves' orbitopathy (GO) may be changing. The aim of the study was to identify trends in presentation of GO to tertiary centres and initial management over time.
Methods: Prospective observational study of European Group On Graves' Orbitopathy (EUGOGO) centres. All new referrals with a diagnosis of GO over a 4-month period in 2012 were included. Clinical and demographic characteristics, referral timelines and initial decisions about management were recorded. The data were compared with a similar EUGOGO survey performed in 2000.
Results: The demographic characteristics of 269 patients studied in 2012 were similar to those collected in the year 2000, including smoking rates (40.0% vs 40.2%). Mild (60.5% vs 41.2%, p<0.01) and inactive GO (63.2% vs 39.9%, p<0.01) were more prevalent in 2012. The times from diagnosis of thyroid disease to being seen in EUGOGO centres (6 vs 16 months) and from first symptoms of GO (9 vs 16 months) or from diagnosis of GO (6 vs 12 months) to first consultation in EUGOGO centres were shorter in 2012 (p<0.01). The initial management plans for GO were no different except surgical treatments for patients with mild inactive disease were more frequently offered in the 2012 cohort than in 2000 (27.3% vs 17%, p<0.05), and selenium supplements were offered only in the 2012 cohort (21.2% vs 0%, p<0.01).
Conclusions: These findings suggest that the clinical manifestations of patients with GO may be changing over time in Europe.
Keywords: Epidemiology; Orbit.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
-
Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).Br J Ophthalmol. 2024 Jan 29;108(2):294-300. doi: 10.1136/bjo-2022-322442. Br J Ophthalmol. 2024. PMID: 36627174 Free PMC article.
-
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.J Clin Endocrinol Metab. 2013 Apr;98(4):1443-9. doi: 10.1210/jc.2012-3873. Epub 2013 Feb 13. J Clin Endocrinol Metab. 2013. PMID: 23408569
-
Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.Orphanet J Rare Dis. 2017 Apr 20;12(1):72. doi: 10.1186/s13023-017-0625-1. Orphanet J Rare Dis. 2017. PMID: 28427469 Free PMC article.
-
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.Eur J Endocrinol. 2008 Mar;158(3):273-85. doi: 10.1530/EJE-07-0666. Eur J Endocrinol. 2008. PMID: 18299459 No abstract available.
-
Evaluating Graves' orbitopathy.Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):229-48. doi: 10.1016/j.beem.2011.11.007. Best Pract Res Clin Endocrinol Metab. 2012. PMID: 22632361 Review.
Cited by
-
How patients experience thyroid eye disease.Front Endocrinol (Lausanne). 2023 Nov 9;14:1283374. doi: 10.3389/fendo.2023.1283374. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027128 Free PMC article.
-
Novel Insight into Non-Genetic Risk Factors of Graves' Orbitopathy.Int J Environ Res Public Health. 2022 Dec 16;19(24):16941. doi: 10.3390/ijerph192416941. Int J Environ Res Public Health. 2022. PMID: 36554821 Free PMC article.
-
Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database.Clin Endocrinol (Oxf). 2025 Apr;102(4):482-489. doi: 10.1111/cen.15183. Epub 2024 Dec 17. Clin Endocrinol (Oxf). 2025. PMID: 39690929 Free PMC article.
-
Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement.Thyroid. 2015 Nov;25(11):1181-4. doi: 10.1089/thy.2015.0222. Epub 2015 Oct 14. Thyroid. 2015. PMID: 26359308 Free PMC article. No abstract available.
-
Graves' Orbitopathy: Report of 82 cases.Tunis Med. 2021 Feb;99(2):243-251. Tunis Med. 2021. PMID: 33899194 Free PMC article. English.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources